OQS
TBPH icon

Occudo Quantitative Strategies’s Theravance Biopharma TBPH Stock Holding History

Occudo Quantitative Strategies’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,849
Closed -$92K – 1010
2024
Q2 		$92K Buy
+10,849
New +$97.9K 0.02% 671
2024
Q1 		– Sell
-49,517
Closed -$557K – 1023
2023
Q4 		$557K Sell
49,517
-7,900
-14% -$79.5K 0.08% 357
2023
Q3 		$496K Buy
57,417
+10,633
+23% +$103K 0.06% 494
2023
Q2 		$484K Buy
+46,784
New +$517K 0.05% 565
2023
Q1 		– Sell
-43,321
Closed -$486K – 1194
2022
Q4 		$486K Buy
+43,321
New +$455K 0.06% 509
2021
Q4 		– Sell
-23,958
Closed -$177K – 1246
2021
Q3 		$177K Buy
+23,958
New +$268K 0.02% 876

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Occudo Quantitative Strategies's TBPH Position: Q3 2024 in Review

Occudo Quantitative Strategies sold out of Theravance Biopharma (TBPH) in Q3 2024, closing a stake of 10,849 shares — an estimated $92K sold.

Occudo Quantitative Strategies first reported a position in TBPH in Q3 2021 and held it in 6 quarters. The position peaked at $557K in Q4 2023. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2024.

  • Occudo Quantitative Strategies reported no remaining Theravance Biopharma position as of Q3 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 10,849 Theravance Biopharma shares in Q3 2024, an estimated $92K.
  • Occudo Quantitative Strategies first reported a position in Theravance Biopharma in Q3 2021 and held it in 6 quarters.
  • Occudo Quantitative Strategies's Theravance Biopharma position peaked at $557K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.